Base de dados : MEDLINE
Pesquisa : D23.050.285.050.119 [Categoria DeCS]
Referências encontradas : 2497 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 250 ir para página                         

  1 / 2497 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29489701
[Au] Autor:Yang Y; Yan S; Tian H; Bao Y
[Ad] Endereço:Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
[Ti] Título:Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
[So] Source:Medicine (Baltimore);97(9):e9994, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Because of the high malignant degree of pancreatic cancer (PC), the early diagnosis of PC is of great concern. Macrophage inhibitory cytokine-1 (MIC-1) was reported to be a potential diagnostic biomarker, but its diagnostic value is indeterminate. Therefore, we performed this meta-analysis to compare it to carbohydrate antigen 19-9 (CA19-9), the most frequently used serum biomarker in PC. MATERIAL AND METHODS: After a systematic review of the relevant studies, the pooled diagnostic indices, including sensitivity, specificity, positive/negative likelihood ratio (PLR/NLR), diagnostic odds ratio (DOR), summary receiver operating characteristic curve (sROC), and area under the SROC curve (AUC) were used to evaluate the diagnostic value of MIC-1 and CA19-9 for PC. These indices were pooled with random-effects models. We explored the heterogeneity by meta-regression. RESULTS: Fourteen studies comprising a total of 2826 subjects were included in our meta-analysis. The summary estimates for MIC-1 and CA19-9 are listed as follows: sensitivity, 80% [95% confidence interval (CI) 78-82] versus 71% (95% CI 68-73); specificity, 85% (95% CI 83-87) versus 88% (95% CI 86-90); DOR, 24.57 (95% CI 14.00-43.10) versus 17.65 (95% CI 11.65-26.76); area under sROC (AUC), 0.8945 versus 0.8322; PLR, 5.18 (95% CI 3.24-8.26) versus 5.34 (95% CI 3.78-7.54); and NLR, 0.23 (95% CI 0.19-0.29) versus 0.32 (95% CI 0.28-0.37). CONCLUSION: These data demonstrate that serum MIC-1 has a comparable diagnostic accuracy to CA19-9 for PC.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno CA-19-9/sangue
Fator 15 de Diferenciação de Crescimento/sangue
Neoplasias Pancreáticas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Razão de Chances
Curva ROC
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (GDF15 protein, human); 0 (Growth Differentiation Factor 15)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009994


  2 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29428036
[Au] Autor:Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
[Ti] Título:Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
[So] Source:Am Surg;84(1):109-113, 2018 Jan 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Because pancreatic cancer is a disease with a dismal prognosis due to the high rate of early recurrence even after curative surgery, selecting the most effective treatment in an individual requires preoperative assessment of the tumor characteristics, including the potential for early recurrence. The study cohort included 84 patients undergoing surgical resection of pancreatic cancer. Univariate and multivariate analyses were conducted to identify the risk factors for early recurrence within six months after curative resection. Early recurrence was associated with a platelet-lymphocyte ratio ≥0.23 (P = 0.04), carbohydrate antigen 19-9 (CA19-9) ≥200 (P = 0.01), and S-pancreas-1 antigen (Span-1) ≥37 (P = 0.0004) by univariate analysis. Multivariate analysis identified CA19-9 ≥200 and Span-1 ≥37 as independent risk factors for early recurrence. Patients with both risk factors had a significantly higher rate of lymph node metastasis than those with no or one risk factor. Span-1 ≥ 37 and CA19-9 ≥ 200 are independent risk factors for early recurrence in patients who underwent surgical resection, and the combination of Span-1 ≥37 and CA19-9 ≥200 is a useful indicator of lymph node metastasis.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Biomarcadores Tumorais/sangue
Antígeno CA-19-9/sangue
Recidiva Local de Neoplasia/diagnóstico
Recidiva Local de Neoplasia/cirurgia
Pancreatectomia
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/cirurgia
[Mh] Termos MeSH secundário: Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Índice de Massa Corporal
Quimioterapia Adjuvante/métodos
Detecção Precoce de Câncer
Feminino
Seguimentos
Seres Humanos
Japão
Estimativa de Kaplan-Meier
Metástase Linfática
Masculino
Meia-Idade
Invasividade Neoplásica
Recidiva Local de Neoplasia/sangue
Recidiva Local de Neoplasia/tratamento farmacológico
Neoplasias Pancreáticas/sangue
Neoplasias Pancreáticas/tratamento farmacológico
Valor Preditivo dos Testes
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Sensibilidade e Especificidade
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (pancreatic associated antigen, SPan-1)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180212
[St] Status:MEDLINE


  3 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369199
[Au] Autor:Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
[Ad] Endereço:Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
[Ti] Título:Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
[So] Source:Medicine (Baltimore);97(4):e9707, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to explore the role of combined pretreatment serum carbohydrate antigen 19-9 (CA19-9) and neutrophil-to-lymphocyte ratio (NLR) as potential prognostic factors in metastatic pancreatic cancer patients.We investigated pretreatment serum CA19-9 and NLR in 59 metastatic pancreatic cancer patients, determined the patients' thresholds by receiver operating characteristic curve analysis, and assessed their prognostic values by Kaplan-Meier curve and Cox regression models.Results of multivariate analysis showed high CA19-9, high NLR, and high score (the scoring system of CA19-9 and NLR) were significantly correlated with overall survival. Area under the curve of the scoring system was higher than that of CA19-9 or NLR.Combined pretreatment serum CA19-9 and NLR is a better prognostic biomarker of metastatic pancreatic cancer patients than CA19-9 or NLR alone.
[Mh] Termos MeSH primário: Antígeno CA-19-9/sangue
Linfócitos
Neutrófilos
Neoplasias Pancreáticas/sangue
[Mh] Termos MeSH secundário: Idoso
Área Sob a Curva
Biomarcadores Tumorais/sangue
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Contagem de Leucócitos
Contagem de Linfócitos
Masculino
Meia-Idade
Análise Multivariada
Neoplasias Pancreáticas/mortalidade
Prognóstico
Modelos de Riscos Proporcionais
Análise de Regressão
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009707


  4 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29378497
[Au] Autor:Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
[Ad] Endereço:1 Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland.
[Ti] Título:Postoperative CEA is a better prognostic marker than CA19-9, hCGß or TATI after resection of colorectal liver metastases.
[So] Source:Tumour Biol;40(1):1010428317752944, 2018 Jan.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liver metastases of colorectal cancer can be operated with a curative intent in selected cases. However, more than half of the patients have a recurrence. The aim of this study was to evaluate the prognostic and predictive value of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), human chorionic gonadotropin ß (hCGß) and tumour-associated trypsin-inhibitor (TATI) in colorectal cancer patients before and 3 months after resection of liver metastases. Marker concentrations were determined in blood samples from 168 colorectal cancer patients, who underwent liver resection between the years 1998 and 2007 at Helsinki University Hospital, Finland. The samples were taken before and 3 months after curative resection. Increased concentrations of CEA (>5 µg/L) and hCGß (>1 pmol/L) 3 months after liver resection correlated with recurrence and impaired overall survival and increased CA19-9 (>26 kU/L) with impaired overall survival, but postoperative TATI was not prognostic. Preoperatively elevated CEA and CA19-9 correlated with impaired overall survival, but not with recurrence. Neither preoperative hCGß nor TATI was prognostic. In conclusion, CEA is a useful prognostic marker, when measured 3 months after resection of colorectal liver metastases. CA19-9 also has prognostic significance and may have additional value.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno CA-19-9/sangue
Antígeno Carcinoembrionário/sangue
Neoplasias Colorretais/patologia
Neoplasias Hepáticas/patologia
Inibidor da Tripsina Pancreática de Kazal/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Gonadotropina Coriônica Humana Subunidade beta/sangue
Neoplasias Colorretais/sangue
Feminino
Seres Humanos
Neoplasias Hepáticas/sangue
Masculino
Meia-Idade
Recidiva Local de Neoplasia/sangue
Recidiva Local de Neoplasia/patologia
Período Pós-Operatório
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (Carcinoembryonic Antigen); 0 (Chorionic Gonadotropin, beta Subunit, Human); 50936-63-5 (Trypsin Inhibitor, Kazal Pancreatic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317752944


  5 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457854
[Au] Autor:Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
[Ad] Endereço:Department of Etiology and tumor marker laboratory, Shanxi Cancer Hospital, Shanxi Province, China.
[Ti] Título:The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
[So] Source:Clin Chim Acta;470:51-55, 2017 Jul.
[Is] ISSN:1873-3492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This study aims to understand the diagnostic value of serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), cancer antigen 15-3 (CA15-3), and tissue polypeptide-specific antigen (TPS) in metastatic breast cancer (MBC). A total of 164 metastatic breast cancer patients in Shanxi Cancer Hospital were recruited between February 2016 and July 2016. 200 breast cancer patients without metastasis in the same period were randomly selected as the control group. The general characteristics, immunohistochemical, and pathological results were investigated between the two groups, and tumor markers were determined. There were statistical differences in the concentration and the positive rates of CEA, CA19-9, CA125, CA15-3, and TPS between the MBC and control group (P<0.05). The highest sensitivity was in CEA and the highest specificity was in CA125 for the diagnosis of MBC when using a single tumor marker at 56.7% and 97.0%, respectively. In addition, two tumor markers were used for the diagnosis of MBC and the CEA and TPS combination had the highest diagnostic sensitivity with 78.7%, while the CA15-3 and CA125 combination had the highest specificity of 91.5%. Analysis of tumor markers of 164 MBC found that there were statistical differences in the positive rates of CEA and CA15-3 between bone metastases and other metastases (χ =6.00, P=0.014; χ =7.32, P=0.007, respectively). The sensitivity and specificity values of the CEA and CA15-3 combination in the diagnosis of bone metastases were 77.1% and 45.8%, respectively. The positive rate of TPS in the lung metastases group was lower than in other metastases (χ =8.06, P=0.005).There were significant differences in the positive rates of CA15-3 and TPS between liver metastases and other metastases (χ =15.42, P<0.001; χ =9.72, P=0.002, respectively). The sensitivity and specificity of the CA15-3 and TPS combination in the diagnosis of liver metastases were 92.3% and 45.6%, respectively, and the positive rate of CEA in triple-negative metastatic breast cancer is lower than in other subtypes (χ =4.80, P=0.028). Therefore, serum CEA, CA19-9, CA125, CA15-3, and TPS can be used in the diagnosis of MBC, and different combinations of tumor markers have varying diagnostic value.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Neoplasias da Mama/sangue
Neoplasias da Mama/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias da Mama/diagnóstico
Antígeno Ca-125/sangue
Antígeno CA-19-9/sangue
Antígeno Carcinoembrionário/sangue
Feminino
Seres Humanos
Meia-Idade
Mucina-1/sangue
Metástase Neoplásica
Peptídeos/sangue
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (CA-19-9 Antigen); 0 (Carcinoembryonic Antigen); 0 (MUC1 protein, human); 0 (Mucin-1); 0 (Peptides); 0 (tissue polypeptide specific antigen)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  6 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277792
[Au] Autor:Miyashita T; Tajima H; Makino I; Okazaki M; Yamaguchi T; Ohbatake Y; Nakanuma S; Hayashi H; Takamura H; Ninomiya I; Fushida S; Kishimoto K; Harmon JW; Ohta T
[Ad] Endereço:Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan tomoharumiya@gmail.com.
[Ti] Título:Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
[So] Source:Anticancer Res;38(1):337-343, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In this study, the effects of neoadjuvant chemotherapy (NAC) on cancer-associated fibroblasts (CAFs) in pancreatic cancer stroma were investigated. MATERIALS AND METHODS: Density of α-smooth muscle actin (αSMA)-positive fibroblasts in resected surgical specimens from untreated patients, patients receiving conventional gemcitabine plus S-1 (GS), and patients receiving gemcitabine plus nab-paclitaxel (GnP) was determined by hybrid cell counting. 18F-Fluorodeoxyglucose positron-emission tomography (FDG-PET) scans and carbohydrate antigen 19-9 (CA19-9) concentrations were used to assess tumor activity before and after chemotherapy in the GnP group. RESULTS: In this retrospective study of 65 patients, αSMA expression was reduced in the GnP group, as revealed by markedly disorganized collagen and a low density of αSMA-positive fibroblasts. There were significantly fewer αSMA-positive fibroblasts in the GnP than in the untreated and GS groups, but there was no significant difference between the latter two groups. αSMA density reflected a decrease in standardized uptake value on FDG-PET, but not CA19-9 concentration, after GnP chemotherapy. CONCLUSION: These data suggest that the GnP regimen induces stromal depletion, resulting in fewer CAFs.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Albuminas/uso terapêutico
Antineoplásicos/uso terapêutico
Fibroblastos Associados a Câncer/patologia
Desoxicitidina/análogos & derivados
Terapia Neoadjuvante/métodos
Paclitaxel/uso terapêutico
Neoplasias Pancreáticas/tratamento farmacológico
Células Estromais/citologia
[Mh] Termos MeSH secundário: Actinas/metabolismo
Adenocarcinoma/patologia
Idoso
Idoso de 80 Anos ou mais
Antígeno CA-19-9/metabolismo
Colágeno/metabolismo
Desoxicitidina/uso terapêutico
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Pâncreas/patologia
Neoplasias Pancreáticas/patologia
Tomografia por Emissão de Pósitrons
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (130-nm albumin-bound paclitaxel); 0 (ACTA2 protein, human); 0 (Actins); 0 (Albumins); 0 (Antineoplastic Agents); 0 (CA-19-9 Antigen); 0W860991D6 (Deoxycytidine); 9007-34-5 (Collagen); B76N6SBZ8R (gemcitabine); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  7 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29072130
[Au] Autor:Chugh M; Piskarev V; Galanina O; Khasbiullina N; Kadam P; Shilova N; Pazynina G; Dobrochaeva K; Bhanushali P; Kozlov N; Tupitsin N; Bovin N
[Ad] Endereço:1 Agappe Diagnostics Ltd, Kochi, India.
[Ti] Título:Glycoprotein CA19.9-specific monoclonal antibodies recognize sialic acid-independent glycotope.
[So] Source:Tumour Biol;39(10):1010428317725434, 2017 Oct.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A repertoire of monoclonal antibodies was generated by immunization of mice with cancer-associated glycoprotein CA19.9, and two of them were selected as optimal capture and detecting counterparts for sandwich test system for detection of CA19.9. Fine epitope specificity of the antibodies was determined using printed glycan array, enzyme-linked immunosorbent assay, and inhibitory enzyme-linked immunosorbent assay. Unexpectedly, both immunoglobulins did not bind key epitope of CA19.9 glycoprotein, tetrasaccharide SiaLe , as well as its defucosylated form sialyl Le (known as CA-50 epitope). The antibodies were found to have different glycan-binding profiles; however, they recognized similar glycotopes with common motif Galß1-3GlcNAcß (Le ), thus resembling specificity of human natural cancer-associated anti-Le antibodies. We propose that cancer-specific glycopeptide epitope includes Galß1-3GlcNAcß fragment of a glycoprotein O-chain in combination with proximal hydrophobic amino acid(s) of the polypeptide chain.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Antígeno CA-19-9/imunologia
Epitopos/imunologia
Neoplasias/imunologia
Trissacarídeos/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais/genética
Antígeno CA-19-9/genética
Epitopos/genética
Glicopeptídeos/genética
Glicopeptídeos/imunologia
Seres Humanos
Camundongos
Ácido N-Acetilneuramínico/genética
Ácido N-Acetilneuramínico/imunologia
Neoplasias/genética
Trissacarídeos/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (CA-19-9 Antigen); 0 (Epitopes); 0 (Glycopeptides); 0 (Trisaccharides); 0 (galactosyl-beta(1-3)-N-acetylglucosaminyl-beta(1-3)galactose); GZP2782OP0 (N-Acetylneuraminic Acid)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171027
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317725434


  8 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29034816
[Au] Autor:Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
[Ad] Endereço:1 Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
[Ti] Título:Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
[So] Source:Tumour Biol;39(10):1010428317730246, 2017 Oct.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Evidence is sparse regarding the clinical performance of luminescent oxygen channeling immunoassays-based tumor marker assays in gynecological cancer. Analyzing serum samples of 336 patients with Dimension™Vista1500, we investigated the diagnostic power of carbohydrate antigen 15-3, carbohydrate antigen 125, carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha-fetoprotein in patients suffering from different types of gynecological cancer and precancerous gynecological diseases and compared findings to appropriate control groups. The cohort comprised 177 female patients with gynecological cancers (73 breast, 22 cervical, 16 endometrial, 17 vulva, and 49 ovarian cancers), 26 patients with precancerous gynecological diseases (11 vulva, 4 cervical, and 10 breast), 109 patients with benign gynecological diseases, and 24 healthy controls. Discriminative power was assessed by areas under the curve in receiver operating characteristic curves, and sensitivities were determined at a fixed specificity of 95%. Levels of biomarkers in healthy controls were in the expected ranges and a discriminative power between gynecological cancers and healthy controls was observed for several tumor markers. Established tumor type-associated markers were elevated in specific gynecological cancers and benign controls as well as within precancerous gynecological diseases and healthy control group. In ovarian cancer, carbohydrate antigen 125 and carbohydrate antigen 15-3 were significantly elevated compared to the respective benign diseases. Carbohydrate antigen 125 was the most conclusive marker (area under the curve = 0.86% and 77.6% sensitivity at 95% specificity). In breast cancer, carcinoembryonic antigen and carbohydrate antigen 15-3 were significantly higher than in the respective benign diseases. Carcinoembryonic antigen achieved the most conclusive area under the curve (0.65) with 31.5% sensitivity at 95% specificity. None of the investigated markers was found to be of value in discriminating benign and malignant cervical diseases. Carcinoembryonic antigen and alpha-fetoprotein distinguished precancerous breast and vulva diseases from healthy controls. These findings show that luminescent oxygen channeling immunoassays-based tumor marker assays provide reliable results in routine diagnostics.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno Ca-125/sangue
Antígeno CA-19-9/sangue
Antígeno Carcinoembrionário/sangue
Neoplasias dos Genitais Femininos/sangue
Mucina-1/sangue
alfa-Fetoproteínas/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antígenos de Neoplasias/sangue
Estudos de Casos e Controles
Feminino
Neoplasias dos Genitais Femininos/patologia
Seres Humanos
Imunoensaio/métodos
Meia-Idade
Curva ROC
Sensibilidade e Especificidade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (CA-19-9 Antigen); 0 (Carcinoembryonic Antigen); 0 (Mucin-1); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171017
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317730246


  9 / 2497 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29023527
[Au] Autor:Zschaeck S; Blümke B; Wust P; Kaul D; Bahra M; Riess H; Klein F; Sinn M; Pelzer U; Budach V; Ghadjar P
[Ad] Endereço:Charité Universitätsmedizin Berlin, Department of Radiation Oncology, Berlin, Germany.
[Ti] Título:Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.
[So] Source:PLoS One;12(10):e0186341, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The role of radiotherapy for unresectable pancreatic cancer is controversial. A benefit of additional radiotherapy is supported by some observations. A dose-effect relationship was recently found by dose escalation employing image guided and intensity modulated radiotherapy. METHODS: We retrospectively evaluated 28 consecutive patients, all with history of extensive prior therapies for unresectable locally advanced/ recurrent pancreatic cancer (LAPC/LRPC). Treatment was delivered by helical tomotherapy after daily position verification with computed tomography. Dose to the planned target volume (PTV) was 51 Gy, while the dose to the macroscopic tumor was escalated by a simultaneous integrated boost to a median cumulative dose of 66 Gy (60-66 Gy). Concomitant chemotherapy consisted mainly of capecitabine (n = 23). RESULTS: 10 of 28 patients presented acute toxicities > grade 2, one patient succumbed to gastrointestinal bleeding after treatment. No correlations of toxicities and dose volume histograms (DVH) of retrospectively delineated small bowel loops were observed, although average small bowel volume receiving ≥ 20 Gy was 374 ml. DVH analyses revealed a correlation of splenic parameters and acute toxicity: Vomiting, anorexia, dehydration, hematologic toxicity, fatigue, combined gastro-intestinal toxicity wit R-values between 0.392 and 0.561 (all p-values > 0.05). Only one patient developed late toxicities > grade 2. With an average follow-up time in surviving patients of 14 months median overall survival time was 19 months and median time to local recurrence 13 months. In 8 patients with available imaging of local recurrence: 5 in field recurrences, 2 marginal recurrences and one lymph node recurrence outside the high dose radiation field were observed. In univariate analysis only ΔCA-19-9 during radiotherapy was associated with local control (p = 0.029) and overall survival (p = 0.049). CONCLUSION: Dose escalated normo-fractionated radiotherapy for LAPC/LRPC seems feasible and suitable to prolong local control and in consequence long-term survival. However, in-field local progression is still frequently observed and possibilities to increase the local effectiveness should be evaluated. Exposure of the spleen was predictive for acute toxicity and should be further investigated.
[Mh] Termos MeSH primário: Neoplasias Pancreáticas/radioterapia
Radioterapia de Intensidade Modulada/métodos
[Mh] Termos MeSH secundário: Idoso
Antineoplásicos/uso terapêutico
Antígeno CA-19-9/sangue
Fracionamento de Dose
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Gradação de Tumores
Recidiva Local de Neoplasia
Neoplasias Pancreáticas/tratamento farmacológico
Neoplasias Pancreáticas/mortalidade
Neoplasias Pancreáticas/patologia
Estudos Retrospectivos
Baço/fisiologia
Baço/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (CA-19-9 Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186341


  10 / 2497 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28931010
[Au] Autor:Lambert A; Jarlier M; Gourgou Bourgade S; Conroy T
[Ad] Endereço:Department of medical oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
[Ti] Título:Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
[So] Source:PLoS One;12(9):e0183288, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hohla et al. suggested that female gender could positively predict response to FOLFIRINOX in patients with advanced pancreatic cancer. In this study, we explored the response to the FOLFIRINOX regimen by gender within the trial PRODIGE4/ACCORD 11. PATIENTS AND METHODS: Data were described by gender, both in FOLFIRINOX group and in the intention-to-treat population of the trial. The relative effect of gender (females in comparison to males) on overall survival (OS) and progression-free survival was estimated by using a Cox proportional hazard model and was presented with the Hazard Ratio and their 95% confidence interval. The analysis of prognostic factors of OS included also: age (older than 65 years), ECOG performance status, primary tumor location, synchronous metastases, number of metastatic sites, hepatic metastasis, pulmonary metastases, lymph node metastases, level of Albumin and level of serum carbohydrate antigen 19-9 and three domains from the EORTC Quality of Life QLQC-30 questionnaire. RESULTS: The FOLFIRINOX group (N = 171 patients) included 106 women (62%) and 65 men. No significant differences were observed between genders regarding demographic and clinical parameters, excepted for lymph nodes metastasis (17% and 35% in women and men respectively; p = 0.012). Median OS was longer for females as compared to males in FOLFIRINOX group (13.1 versus 10.3 months respectively; HR = 0.73; 95% CI, 0.51-1.06). Similarly, median PFS was superior (7.2 versus 5.9 months; HR = 0.79; 95% CI, 0.57-1.10). Nevertheless, in both cases, the differences were not statistically significant (p = 0.10 et p = 0.169, respectively). CONCLUSIONS: In this study, the overall survival and progression-free survival rates were not significantly higher for females than for males in FOLFIRINOX group (HR = 0.73; 95% CI, 0.51-1.06 and HR = 0.79; 95% CI, 0.57-1.10 respectively). Even if the percentage of patients with lymph node metastasis is higher for males than for females, the interaction between gender and lymph node metastasis was non-significant. Our exploratory analysis did not permit to definitively conclude about a possible effect of gender on the prognosis of patients under FOLFIRINOX. This subject deserves further evaluation. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT00112658. KEY MESSAGE: Our analysis suggests that FOLFIRINOX, as first-line option for patients with metastatic pancreatic cancer who are younger than 76 years and who have a good performance status (ECOG 0 or 1), no cardiac ischemia and normal or nearly normal bilirubin levels, is beneficial, but not particularly in female patients.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Pancreáticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígeno CA-19-9/análise
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Intervalo Livre de Doença
Feminino
Seres Humanos
Neoplasias Hepáticas/secundário
Neoplasias Pulmonares/secundário
Metástase Linfática
Masculino
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Pancreáticas/mortalidade
Neoplasias Pancreáticas/patologia
Prognóstico
Modelos de Riscos Proporcionais
Qualidade de Vida
Fatores Sexuais
Taxa de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (CA-19-9 Antigen); 0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183288



página 1 de 250 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde